Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study

por Xu, Ming‐Hao, Huang, Cheng, Li, Mei‐Ling, Zhu, Xiao‐Dong, Tan, Chang‐Jun, Zhou, Jian, Fan, Jia, Sun, Hui‐Chuan, Shen, Ying‐Hao
Publicado 2023

The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcino...

por Shen, Ying-Hao, Huang, Cheng, Zhu, Xiao-Dong, Xu, Ming-Hao, Chen, Zhao-Shuo, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan
Publicado 2022

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

por Huang, Cheng, Zhu, Xiao-Dong, Shen, Ying-Hao, Wu, Dong, Ji, Yuan, Ge, Ning-Ling, Chen, Ling-Li, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan
Publicado 2021

Activation of PI3K/AKT and MAPK Pathway through a PDGFRβ-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular Carcinoma

por Li, Quan-Lin, Gu, Fang-Ming, Wang, Zheng, Jiang, Jia-Hao, Yao, Li-Qing, Tan, Chang-Jun, Huang, Xiao-Yong, Ke, Ai-Wu, Dai, Zhi, Fan, Jia, Zhou, Jian
Publicado 2012

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

por Huang, Cheng, Zhu, Xiao-Dong, Shen, Ying-Hao, Xu, Bin, Wu, Dong, Ji, Yuan, Chen, Ling-Li, Song, Tian-Qiang, Zhang, Wei, Zeng, Zhi-Ming, Huang, Hua-Sheng, Wang, Kui, Huang, Lan-Qing, Chen, Yong-Jun, Yang, Yu-Chen, Zhou, Le-Du, Long, Guo, Zhao, Hai-Tao, Wang, Yun-Chao, Ge, Ning-Ling, Chen, Yi, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan
Publicado 2023